Compare GSK plc (GSK) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs S&P Global Inc — how do they compare? GSK plc trades at $50.33 (market cap $102.60B), while S&P Global Inc trades at $410.94 (market cap $120.48B). The key difference: S&P Global Inc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GSK | SPGI | |
|---|---|---|
Market Cap | $102.60B | $120.48B |
Sector | Health | Financials |
52-Week High | $61.18 | $534.79 |
52-Week Low | $38.22 | $370.42 |
Enterprise Value | $123.04B | $131.97B |
Dividend Yield | 3.57% | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
S&P Global (SPGI) trades at $410.26, down 0.17% on the day, with a bearish technical signal from moving averages and ADX. The company reported strong Q2 2026 earnings of $4.83 per share, beating estimates, and maintains robust profitability with a 30.54% net income margin. Recent news highlights expansion in AI and data collaborations, including integration with Microsoft 365 Copilot.
The outlook remains positive with 86% analyst buy ratings and a $523.20 consensus price target, implying significant upside. Risks include competitive pressures and reliance on financial market health. Revenue growth and strategic partnerships support long-term value, but investors should monitor execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
